DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...
Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...
It has had strong momentum since November, but there is still plenty of upside left.
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...
Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...
StockStory.org on MSN
DexCom (DXCM) stock trades down, here is why
What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results